4568. Guanoxan

Nomenclature

CAS number: 2165-19-7
[(2,3-Dihydro-1,4-benzodioxin-2-yl)methyl]guanidine; (1,4-benzodioxan-2-ylmethyl)guanidine; 2-guanidinomethyl-1,4-benzodioxan.
C10H13N3O2; mol wt 207.23.
C 57.96%, H 6.32%, N 20.28%, O 15.44%.

Description and references

Prepn: BE 632701; J. Augstein, S. M. Green, US 3247221 (1963, 1966, both to Pfizer); Monro, Chem. Ind. (London) 1964, 1806; Gardner, GB 996708 (1965 to SKF), C.A. 63, 14877d (1965); Yu, Shen, C.A. 66, 94969k (1967). Prepn and properties of (+) and ()-forms: Stenlake et al., J. Pharm. Pharmacol. 20 (Suppl), 82 (1968). Pharmacology: Augstein et al., J. Med. Chem. 8, 446 (1965); Cession-Fossion, Arch. Int. Pharmacodyn. Ther. 164, 419 (1966); Vidal-Beretewide et al., Arzneim.-Forsch. 19, 947 (1969). Metabolic studies: Jack et al., J. Pharm. Pharmacol. 23, 2225 (1971); Xenobiotica 2, 35 (1972).

Chemical structure

Properties

Crystals, mp 164-165°.

Derivative

Sulfate.

Nomenclature

CAS number: 5714-04-5
Envacar (Pfizer).
(C10H13N3O2)2.H2SO4; mol wt 512.54.
C 46.87%, H 5.51%, N 16.40%, O 24.97%, S 6.26%.

Therapeutic Category

Antihypertensive.

Keywords

Antihypertensive; Guanidine Derivatives